NasdaqCM:CRDFBiotechs
Cardiff Oncology (CRDF) Valuation Check After New Onvansertib Phase 2 Data And Leadership Changes
Why Cardiff Oncology is back on investors’ radar
Cardiff Oncology (CRDF) has drawn fresh attention after reporting dose dependent Phase 2 data for onvansertib in first line RAS mutated metastatic colorectal cancer, while also announcing a leadership shake up, including a new interim CEO.
See our latest analysis for Cardiff Oncology.
The encouraging onvansertib data and leadership changes have arrived during a weak share price stretch, with a 7 day share price return of 45.6% decline and a 1...